Cipla's InvaGen New York facility gets USFDA's No Action Indicated classification
Cipla said the USFDA has classified the inspection of InvaGen Pharmaceuticals' manufacturing facility in New York as No Action Indicated. The inspection was conducted from October 19 to October 22, 2026, and the classification was communicated on November 17.
\